Bayer Will Submit More Data To FDA On Aspirin MI Prevention Labeling
This article was originally published in The Tan Sheet
Executive Summary
Bayer will submit additional data on subpopulation risks associated with aspirin therapy to support its citizen petition requesting amended professional labeling for primary prevention of myocardial infarction
You may also be interested in...
WHS Findings Back Expanded Aspirin Professional Labeling – Bayer
Results from the Women's Health Study showing the effects of aspirin therapy in women support Bayer Consumer Care's citizen petition requesting expanded professional labeling, the firm says
WHS Findings Back Expanded Aspirin Professional Labeling – Bayer
Results from the Women's Health Study showing the effects of aspirin therapy in women support Bayer Consumer Care's citizen petition requesting expanded professional labeling, the firm says
WHS Findings Back Expanded Aspirin Professional Labeling – Bayer
Results from the Women's Health Study showing the effects of aspirin therapy in women support Bayer Consumer Care's citizen petition requesting expanded professional labeling, the firm says